ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.

  • By

  • June 14, 2026

  • 4 min

Share

  • 1

    The phase 2 ImmunoPRISM trial evaluated teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.

  • 2

    Teclistamab achieved a complete response in 75.6% of patients, while none in the lenalidomide plus dexamethasone group achieved this.

  • 3

    Among evaluable patients, 82% in the teclistamab group became minimal residual disease-negative, compared to none in the combination therapy group.

  • 4

    Teclistamab significantly improved progression-free survival, with only 7% of patients progressing after 23.4 months, versus 36% in the combination group.

  • 5

    Cytokine release syndrome occurred in 71% of teclistamab patients, but all cases were low grade, with no neurological toxicities reported.

Original Source(s)

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

  • by

  • June 14, 2026

Related Content

Erin Gillaspie, M.D. M.P.H., Joins Baptist Health Herbert Wertheim Cancer Institute as Chief of Thoracic Surgery

Erin Gillaspie, M.D., M.P.H., has joined Baptist Health Herbert Wertheim Cancer Institute and Baptist Health Cancer Care as chief of thoracic surgery.

  • by

  • November 3, 2026

  • 3 min
Roswell Park is a Center of Excellence for Rectal Cancer Surgery

Roswell Park Comprehensive Cancer Center is a nationally accredited and certified Center of Excellence for colorectal cancer surgery due to the high volume of procedures completed annually for patients with colon and rectal cancer.

  • October 27, 2026

  • 2 min
Two ‘forever chemicals’ associated with higher risk of aggressive breast cancer in NIH analysis